COMP <GO>
SBC vs MRK // NET PROFIT MARGIN
SBC Medical Group Holdings Incorporated (NASDAQ) VS. Merck & Company Inc. (NYSE) • 15-METRIC TALLY: SBC 8
— MRK 5
▲ NET PROFIT MARGIN LEADER: SBC
LAST: $5.28 (-7.29%) • MKT CAP: $585.2M
net-margins
29.40%
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
net-margins
28.10%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SBC VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | SBC | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 73.30% | 74.80% | -1.50 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 63.10% | 20.70% | +42.40 | SBC | /roic <GO> |
| EV/EBITDA & P/E Valuation | 6.1x | 15.3x | -9.20 | SBC | /valuation <GO> |
| Free Cash Flow Yield | 3.98% | 3.42% | +0.56 | SBC | /fcf-yield <GO> |
| Operating Margin | 38.90% | 34.30% | +4.60 | SBC | /operating-margins <GO> |
| Net Profit Margin ACTIVE | 29.40% | 28.10% | +1.30 | SBC | /net-margins <GO> |
| Revenue Growth (YoY) | -15.50% | 1.30% | -16.80 | MRK | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 5.46 | 5.19 | +0.27 | SBC | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 7/9 | -1.00 | MRK | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 59.6 | 51.7 | +7.90 | SBC | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.92 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 10.7x | 18.4x | -7.70 | SBC | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $585.2M | $361.02B | -$360.44B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | SBC REV | MRK REV | SBC GROSS % | MRK GROSS % | SBC FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $173.6M | $65.01B | 73.3% | 74.8% | $23.3M | $12.36B |
| FY 2024 | $205.4M | $64.17B | 76.0% | 76.3% | $18.0M | $18.10B |
| FY 2023 | $193.5M | $60.12B | — | — | $50.7M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SBC // BETA —
MRK // BETA 0.92